Biotricity INC 10-Q quarterly reports

Biotricity Inc. reported significant revenue growth and improved operating profit for the nine months ended December 31, 2025, despite ongoing net losses and working capital challenges.

Biotricity Inc. announced significant revenue growth and a second consecutive quarter of positive operating profit, despite ongoing liquidity concerns and a substantial accumulated deficit.

Biotricity Inc. reported its first-ever positive profit from operations and fourth consecutive quarter of positive free cash flow, driven by strong revenue growth and improved gross margins.

Biotricity Inc. files an amended quarterly report to correct clerical errors, while still facing substantial doubt about its ability to continue as a going concern.

Biotricity Inc. announces revenue growth and reduced operating expenses for the quarter ended December 31, 2024, signaling progress towards profitability.

Biotricity Inc. announced a 9.4% year-over-year increase in revenue for the six months ended September 30, 2024, alongside significant improvements in gross margin and operating expense management.

Biotricity Inc. announced its first quarter 2025 results, highlighting revenue growth and strategic efforts to simplify the balance sheet through debt and equity conversions.

Biotricity Inc. saw a 21% increase in revenue year-over-year in Q3 2024, driven by growth in technology fees and device sales, while also reducing operating expenses.